Research Peptide Vials
Tesamorelin
Tesamorelin (usan) is indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy and is not recommended for weight loss. Tesamorelin is known for targeting visceral fat specifically, which is the fat linked to higher health risks
Product Name: | Tesamorelin |
Synonyms: | D06655;Tesamorelin (usan);TesamorelinAcetate;Hot selling Pharmaceutical peptides 2mg Tesamorelin 99%;Tesamorelin (usan) USP/EP/BP;TIANFUCHEM--218949-48-5---Tesamorelin (usan);Adipotide/FTTP;tesamorel |
CAS: | 218949-48-5 |
MF: | C221H366N72O67S |
MW: | 5135.86 |
EINECS: | 603-809-2 |
Tesamorelin (usan) consists of the 44 amino acid sequence of human growth hormone releasing factor (GRF), with a 3-hexenoyl group attached to its tyrosine N-terminal residue. It is a new growth hormone releasing factor analogue, which can not only restore normal growth hormone secretion in the body, but also reduce the increased visceral adipose tissue (VAT), improve blood lipid abnormalities and quality of life, and maintain glucose homeostasis in the body.